- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05534087
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) (CLAUDIA)
A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
About 25% of resectable high-risk stage 2 or stage 3 colon cancers are known to relapse despite standard treatments, including radical resection and adjuvant chemotherapy.
Using circulating tumor DNA (ctDNA)-based minimal residual cancer (MRD) detection technology, patients whose MRD is not eradicated after adjuvant chemotherapy could be identified. Early introduction of intensified chemotherapy for this group of patients could prolong survival time and increase cure rates.
This study is part of the Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (CLADIA Colon Cancer). Part 1 of the platform study (Prospective Observational Study of ctDNA Monitoring During Adjuvant) is a large-scale, prospective observational study that follows ctDNA up to three years after resection in about 1,200 patients with stage 2-3 colon cancer.
This study (Part 2) aims to study the efficacy of early intensified chemotherapy (3 months of modified FOLFIRINOX ) compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Youngjun Cha, MD
- Phone Number: 82-2-2072-0795
- Email: yongjuncha@ncc.re.kr
Study Contact Backup
- Name: Sae-Won Han, MD,PhD
- Phone Number: 82-2-2072-0795
- Email: saewon1@snu.ac.kr
Study Locations
-
-
-
Goyang, Korea, Republic of
- Recruiting
- National Cancer Center
-
Contact:
- Yongjun Cha
-
Seongnam, Korea, Republic of
- Recruiting
- Jin Won Kim
-
Contact:
- Jin Won Kim
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Hospital
-
Contact:
- Sae-Won Han
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who willingly consented and signed the informed consent form to participate in the study
- Age range of 19 to 75 years
- Adenocarcinoma of colon confirmed by histology
- Patients with stage II-III colon cancer as defined by the American Joint Committee on Cancer's eighth edition (Stage II cancer is limited to patients who are at a high risk, with more than one risk factor for recurrence.)
- Patients who have completed the sixth cycle of FOLFOX or the fourth cycle of CAPOX adjuvant chemotherapy for colon cancer following radical resection (R0 resection)
- A ctDNA test performed 3 to 6 weeks after surgery reveals a positive MRD
- ECOG performance scale of 0-1 (only 1 is allowed for 70-75 years old)
- Adequate bone marrow function [ANC ≥1,300/LL, platelets ≥75,000/LL, hemoglobin ≥8.0g/dL (may be eligible in study if intermittent transfusion is required)]
- Appropriate liver function (total bilirubin ≤1.5xULN, AST and ALT ≤3xULN)
- Appropriate renal function (serum creatine ≤1.5xULN, renal clearance rate ≥50 ml/min)
- Patients who are deemed to understand the study protocol and are willing to participate in the trial until it is completed
Exclusion Criteria:
- Pregnant or lactating women
- Pregnant women who had a positive pregnancy test at the time of the baseline examination (postmenopausal women must be amenable for at least 12 months to be considered non-fertility)
- Sexually active men and women of reproductive age who are unwilling to use contraception throughout the study treatment and for a period of 6 months (female) or 3 months (male) following the discontinuation of study treatment
- Clinically significant heart condition [unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure, or significant heart arrhythmia above NYHA II, or acute coronary syndrome, including myocardial infarction within the last 6 months]
- Active viral infections such as HIV (However, HBV carriers may enroll if their HBV DNA titer is less than 20,000 IU/ml, and antiviral drugs for hepatitis B may be administered prophylactically at the investigator's discretion)
- Significant uncontrolled infections or other uncontrolled comorbidities
- Symptomatic inflammatory bowel disease
- Allogeneic transplantation history necessitating immunosuppressive therapy
- A history of other malignancies identified within the last three years, except for completed removed basal cell carcinoma of the skin, completely removed cervical epithelial carcinoma, and thyroid cancer that has been treated, including surgery
- Recurrent or residual disease identified clinically or radiographically
- Previous history of irinotecan treatment
- Polyposis including familial adenomatous polyps
- Two or more colon or rectal cancers with a pathologic stage greater than II that were detected concurrently or within the last three years
- When the investigator determines that the subjects' safety may be jeopardized during the study because of other serious or unstable pre-existing medical or mental conditions
- Prior clinical trial participation and usage of investigational drugs or devices following radical resection of colon cancer
- Patients with peripheral neuropathy who have a CTCAE v5 grade 3 or higher functional disability (corresponds to "severe symptoms, limiting self-care activity of daily living" according to CTCAE v5 criteria)
- Previous anaphylactic reaction or severe and unexpected reactions to fluoropyrimidines or platinum
- Gilbert's syndrome, dehydro-pyridine dehydrogenase (DPD) deficiency, or homozygous UGT1A1*28 alleles
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mFOLFIRINOX intensified chemotherapy
6 cycles of mFOLFIRINOX - Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks |
(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks
Other Names:
|
Active Comparator: FOLFOX or CAPOX adjuvant chemotherapy
FOLFOX 6 cycles or CAPOX 4 cycles
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year disease-free survival rate
Time Frame: Through completion of follow-up (estimated to be 36 months)
|
The rate refers to cases that see first tumor metastasis or recurrence or death of any cause from randomization
|
Through completion of follow-up (estimated to be 36 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Circulating tumor DNA (ctDNA) clearance rate
Time Frame: The data of ctDNA clearance rate will be collected at 10 time points
|
The proportion of patients with circulating tumor DNA clearance after 36months study treatment.
|
The data of ctDNA clearance rate will be collected at 10 time points
|
5-year overall survival rate (5y-OS rate)
Time Frame: Through completion of follow-up (estimated to be 60 months)
|
Overall survival is defined as the time from beginning of study treatment until death due to any cause.
|
Through completion of follow-up (estimated to be 60 months)
|
Treatment-Related Adverse Events
Time Frame: Through completion of follow-up (estimated to be 36 months)
|
The number of patients with adverse events and the severity according to CTCAE v5.0.
|
Through completion of follow-up (estimated to be 36 months)
|
EORTC QLQ-C30 scale
Time Frame: Through completion of follow-up (estimated to be 36 months)
|
Using the EORTC QLQ-C30 scale (European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30) to evaluate the quality of life of patients.
|
Through completion of follow-up (estimated to be 36 months)
|
Collaborators and Investigators
Investigators
- Study Director: Youngjun Cha, MD, Natioal Cancer Center South Korea
- Principal Investigator: Sae-Won Han, MD,PhD, Seoul National University Hospital South Korea
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
Other Study ID Numbers
- H-2205-029-1322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on mFOLFIRINOX-FOLFIRI intensified chemotherapy
-
Institute of Oncology LjubljanaUnknown
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
Institut de Cancérologie de LorraineActive, not recruiting
-
Associazione Italiana per lo Studio del PancreasGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente; High Research...RecruitingPancreas Ductal AdenocarcinomaItaly
-
The First People's Hospital of ChangzhouCompleted
-
Karen-Lise Garm SpindlerRecruitingColorectal Cancer | Adjuvant Chemotherapy | Circulating Tumor DNA | Progression Free SurvivalDenmark
-
Institut CurieUNICANCERCompletedEwing Sarcoma Family of TumorsFrance
-
Xu jianminUnknownNeoplasm Metastasis | Liver Neoplasms | Colorectal NeoplasmsChina
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
National Center for Tumor Diseases, HeidelbergPfizer; Roche Pharma AGTerminated